Airsculpt Technologies Inc Dossier - Source-backed chat

Airsculpt Technologies Inc

AIRSNASDAQ

SectorHealth Care

IndustryHealth Care Providers & Services

Beta (adjusted)1.90

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.76Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $126.9M

Enterprise Value $151.6M

Shares Outstanding 71.5M diluted

Moat Rating None

Next Earnings Date9 Nov 2026

Last ex-dividend25 Aug 2022

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AirSculpt Technologies is showing early signs of operational stabilization under its refreshed marketing strategy and leadership team, highlighted by positive same-center sales growth of 1% in Q1 2026. However, the company continues to face headwinds from post-COVID normalization in the aesthetics industry, elevated leverage, and recent accounting delays related to inter-company transactions. While the emerging opportunity to serve patients undergoing GLP-1 weight loss treatments represents a strong long-term catalyst, a 'Hold' rating is recommended until sustained profitability and clean financial reporting are established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.50

Mean target$6.25

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.5015%

Consumer discretionary spending weakens further, causing high-ticket elective procedure volumes to decline. Additionally, persistent internal control weaknesses or further delays in financial reporting damage investor confidence, pushing the stock down as liquidity tightens.

Base CaseCentral scenario

$4.5060%

AirSculpt achieves its full-year 2026 guidance of $151 million to $157 million in revenue and $15 million to $17 million in Adjusted EBITDA. Same-store sales remain flat to slightly positive, and the company continues to pay down debt using ATM proceeds, stabilizing its balance sheet.

Bull CaseUpside scenario

$6.5025%

The refreshed marketing strategy successfully drives double-digit same-store sales growth, and the company captures a significant share of the post-GLP-1 body contouring market (loose skin and stubborn fat treatments), driving annual revenues above $170 million and expanding Adjusted EBITDA margins.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary, minimally invasive awake body contouring technology with high patient satisfaction and quick recovery times.
Significant long-term growth catalyst from GLP-1 weight loss patients requiring skin tightening and residual fat removal.
Refreshed marketing strategy showing early success with positive same-center sales trends in early 2026.

Key Investment Risks

High sensitivity to macroeconomic cycles and consumer discretionary spending, given the high out-of-pocket cost of procedures ($12,000–$13,000 average ticket).
Material weaknesses in internal controls over financial reporting, as evidenced by the delayed filing of the 2025 Form 10-K.
Elevated leverage and reliance on dilutive ATM equity programs to pay down outstanding debt.

Thesis Invalidation Triggers

Failure to meet the lower bound of the FY 2026 revenue guidance ($151 million).
A material restatement of historical financial statements during the finalization of inter-company accounts.
A sharp decline in quarterly case volumes below 2,500.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.